Información General sobre Enfermedad Renal Crónica y anemia
2006
USRDS 2006
U.S. Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
2006 Jul
Wikström B, Gutierrez A, Jacobson S, Prütz K-G, Weiss L.
Time gain with every other week administration of erythropoiesis-stimulating agents to patients in hemodialysis.
Nephrol Dial Transplant 2006 July;21(Suppl 4): (Abstract SP451).
2005
USRDS 2005
U.S. Renal Data System, USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
2005 Nov-Dec
Sullivan T, Mun Y, Wallace JF, Patton JF.
Advances in conducting retrospective chart review studies: use of electronic report formas and database in a community study in anemic patients with myelodysplastic syndrome.
J Support Oncol. 2005 Nov-Dec;3(6 Suppl 4):12-3.
2005 Apr-Jun
Bennett L, Alonso MA.
Current practice in renal anaemia management: two multinational surveys.
EDTNA ERCA J. 2005 Apr-Jun;31(2):99-103.
2005 Mar
Osinski M, Wish J.
Physician workforce: coming up short.
Nephrol News Issues. 2005 Mar;19(4):58-9, 64, 67
2004 Jan-Mar
Mahon A, Docherty B.
2004 Jan-Mar
Moore T, Chookie S.
Extended dosing of darbepoetin alfa in patients with chronic kidney disease not on dialysis: a review of recent data.
Nephrol Nurs J. 2004 Jan-Mar;30(1):34-7.
2003 Sep
Stengel B, Billon S, Van Dijk PC, Jager KJ, Dekker FW, Simpson K, Briggs JD.
Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe.
Nephrol Dial Transplant. 2003 Sep;18(9):1824-33..
2002 Nov
De Cock E, Van Bellingham L, Standaert B.
Assessing provider time for anaemia management of dialysis patients using time & motion methods: a multi-centre observational study in Europe.
Value Health. 2002 Nov;5:581.
2002 Jan
Lysaght MJ.
Maintenance dialysis population dynamics: current trends and long-term implications.
J Am Soc Nephrol. 2002 Jan;13 Suppl 1:S37-40.
1997 May
Neilson EG, Hull AR, Wish JB, Neylan JF, Sherman D, Suki WN.
The Ad Hoc Committee report on estimating the future workforce and training requirements for nephrology.
The Ad Hoc Committee on Nephrology Manpower Needs. 1997 May;8(5 Suppl 9):S1-4.
Tratamiento eficaz de la anemia renal y variabilidad de la hemoglobina
2006 Jul
Gilbertson D, Ebben J, Collins A.
The effect of haemoglobin variability on hospitalization and mortality.
Nephrol Dial Transplant 2006 Jul; 21 (Suppl 4): iv169
2005 Sep
Fishbane S, Berns JS.
Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.
Kidney Int 2005 Sep;68(3):1337-43.
2005 Sep
Collins AJ, Brenner RM, Ofman JJ.
Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
Am J Kidney Dis 2005 Sep;46(3):481-8.
2005
Ebben J, Gilbertson DT, Collins AJ.
Short-term variability of hemoglobin levels in ESRD patients.
J Am Soc Nephrol 2005; 16: 486A.
2005 Jun
Stirling CM, Patel JK, Simpson K.
Haemoglobin target for haemodialysis patients – is it achievable?
Nephrol Dial Transplant. 2005 Jun;20(Suppl 5):v268 (abstract MP202).
2005 May
Jacobs C, Frei D, Perkins AC.
Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
Nephrol Dial Transplant. 2005 May;20(Suppl 3):iii3-iii24.
2004 Jul
Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK.
Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Am J Kidney Dis. 2004 Jul;44(1):94-111.
2004 Jan
Port FK, Pisoni RL, Bragg-Gresham JL, Satayathum SS, Young EW, Wolfe RA, Held PJ.
DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States.
Blood Purif. 2004 Jan;22(1):175-80.
2003 Oct
Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, DeOreo PB.
Hemoglobin variability in epoetin-treated hemodialysis patients.
Kidney Int. 2003 Oct;64(4):1514-21.
2003 May
Ofsthun N, LaBrecque J, Lacson E, Keen M, Lazarus JM.
The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients.
Kidney Int. 2003 May;63(5):1908-14.
2003 Jan
Lacson E Jr, Ofsthun N, Lazarus JM.
Effect of variability in anemia management on hemoglobin outcomes in ESRD.
Am J Kidney Dis. 2003 Jan;41(1):111-24.
Publicaciones referentes en anemia renal
2007 Feb
Levin A.
Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR.
Nephrol Dial Transplant. 2007 Feb;22(2):309-12.
2007 Feb
Bunn HF.
2006 Nov
Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators.
Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
N Engl J Med. 2006 Nov 16;355(20):2071-84. Comment in: N Engl J Med. 2006 Nov 16;355(20):2144-6.
2006 Nov
Remuzzi G, Ingelfinger JR.
2006 Nov
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators.
Correction of anemia with epoetin alfa in chronic kidney disease.
N Engl J Med. 2006 Nov 16;355(20):2085-98. Comment in: N Engl J Med. 2006 Nov 16;355(20):2144-6.
2006 Sep
Macdougall IC, Eckardt KU
Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia.
Lancet. 2006 Sep 9;368(9539):947-53.
2005 Oct
Ble A, Fink JC, Woodman RC, Klausner MA, Windham BG, Guralnik JM, Ferrucci L.
Renal function, erythropoietin, and anemia of older persons: the InCHIANTI study.
Arch Intern Med. 2005 Oct 24;165(19):2222-7.
2005 May
Chatterjee PK.
Pleiotropic renal actions of erythropoietin.
Lancet. 2005 May 28-Jun 3;365(9474):1890-2.
2005 Jan
Maiese K, Li F, Chong ZZ.
[No date]
National Kidney Foundation KDOQI
V. Clinical practice recommendations for anemia in chronic kidney disease in transplant recipients.
1998 Aug
Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA.
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
Engl J Med. 1998 Aug 27;339(9):584-90.
1993 Jan
Rao DS, Shih MS, Mohini R.
Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia.
N Engl J Med. 1993 Jan 21;328(3):171-5
1991 Mar
Nissenson AR, Nimer SD, Wolcott DL.
Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects.
Ann Intern Med. 1991 Mar 1;114(5):402-16.
1991 Feb
Taylor JE, Henderson IS, Mactier RA, Stewart WK.
1990 Mar
[No authors listed] Canadian Erythropoietin Study Group.
Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis.
BMJ. 1990 Mar 3;300(6724):573-8.
1987 Jan
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW.
Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
N Engl J Med. 1987 Jan 8;316(2):73-8.
Tratamientos innovadores
2007 Feb
Bunn HF.
New agents that stimulate erythropoiesis.
Nephrol Dial Transplant 2006 Jul; 21 (Suppl 4): iv169
2006 Dec
de Francisco AL, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V, Metivier F, Dougherty FC, Oguey D; BA16260 Study Invesigators.
Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study International
Journal of Clinical Practice 2006 Dec;60(12):1687-96
2006 Dec
Kerr PG.
Renal anaemia: Recent developments, innovative approaches and future directions for improved management (Review Article).
Nephrology (Carlton). 2006 Dec;11(6):542-8.
2006 Dec
Rastogi A, Nissenson AR.
New approaches to the management of anemia of chronic kidney disease: Beyond Epogen and Infed.
Kidney Int Suppl. 2006 Dec;(104):S14-6.
2006 Nov
Macdougall I, et al.
Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Chronic Kidney Disease.
Clin J Am Soc Nephrol. 2006 Nov;1:1211-1215.
2006 Oct
Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, Green JM, Schatz PJ, Woodburn KW.
Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.
Exp Hematol. 2006 Oct;34(10):1303-11
2006 Oct
Sharma B, Ryan MH, Boven K.
Reactions to Eprex's adverse reactions.
Nat Biotechnol. 2006 Oct;24(10):1199-200; author reply 1200.
2006 Sep
Macdougall IC, Eckardt KU.
Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia.
Lancet. 2006 Sep 9;368(9539):947-53.
2006 Sep
Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM.
Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.
2006 Sep 15;108(6):1830-4.
2006
Sulowicz W.
C.E.R.A. (Continuous Erythropoietin Receptor Activator): A new perspective in anaemia management.
BANTAO Journal 2006:4:77-80.
2006 Jul
Macdougall IC.
Recent advances in erythropoietic agents in renal anemia.
Semin Nephrol. 2006 Jul;26(4):313-8.
2006 Jun
Schellekens H, Jiskoot W.
Eprex-associated pure red cell aplasia and leachates.
Nat Biotechnol. 2006 Jun;24(6):613-4.
2006 Jun
Bernhardt WM, Campean V, Kany S, Jurgensen JS, Weidemann A, Warnecke C, Arend M, Klaus S, Gunzler V, Amann K, Willam C, Wiesener MS, Eckardt KU.
Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure.
J Am Soc Nephrol. 2006 Jul;17(7):1970-8. Epub 2006 Jun 8.
2005 Nov
Macdougall IC.
CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.
Curr Hematol Rep. 2005 Nov;4(6):436-40.
2005
Crommelin D, Bermejo T, Bissig M, Damiaans J, Kramer I, Rambourg P, Scroccaro G, Strukelj B, Tredree R, Ronco C.
Biosimilars, generic versions of the first generation of therapeutic proteins: do they exist?
Contrib Nephrol. 2005;149:287-94.
2005 May
Schellekens H.
Follow-on biologics: challenges of the "next generation".
Nephrol Dial Transplant. 2005 May;20 Suppl 4:iv31-36.
Sea el primero en estar informado
Suscríbase a las publicaciones más recientes, a las noticias y a los anuncios de diversos eventos
